Global Blood Therapeutics (GBT) PT Lowered to $65 at Stifel, Expect Near Term Sentiment to be Dominated by Fulcrum's FTX-6058 Data
Tweet Send to a Friend
Stifel analyst Benjamin Burnett lowered the price target on Global Blood Therapeutics (NASDAQ: GBT) to $65.00 (from $68.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
